Proteome analysis of schizophrenia brain tissue

References

• Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, . 2005. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58:85–96.
   PubMed Web of Science ®Google Scholar
• Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, Gory-Fauré S, . 2002. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 16:2350–2364.
   PubMed Web of Science ®Google Scholar
• Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. 2007. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62:711–721.
   PubMed Web of Science ®Google Scholar
• Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77:858–866.
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR. 2000. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 165:6576–6582.
   PubMed Web of Science ®Google Scholar
• Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. 2006. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 6:3414–3425.
   PubMed Web of Science ®Google Scholar
• Behan A, Byrne C, Dunn MJ, Cagney G, Cotter DR. 2009. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 14:601–613.
   PubMed Web of Science ®Google Scholar
• Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. 2004. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3:515–533.
   Google Scholar
• Ben-Shachar D. 2002. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83:1241–1251.
   PubMed Web of Science ®Google Scholar
• Ben-Shachar D, Laifenfeld D. 2004. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59:273–296.
   PubMed Web of Science ®Google Scholar
• Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, Klein E. 1999. Increased mitochondrial complex I activity in platelets of schizophrenia patients. Int J Neuropsychopharmacol 2:245–253.
   PubMed Web of Science ®Google Scholar
• Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. 2003. Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol Sci 24:486–492.
   PubMedGoogle Scholar
• Birner R, Nebauer R, Schneiter R, Daum G. 2003. Synthetic lethal interaction of the mitochondrial phosphatidylethanolamine biosynthetic machinery with the prohibitin complex of Saccharomyces cerevisiae. Mol Biol Cell 14:370–383.
   PubMedGoogle Scholar
• Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT, Tooney PA. 2006. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82:175–183.
   PubMed Web of Science ®Google Scholar
• Brockschnieder D, Sabanay H, Riethmacher D, Peles E. 2006. Ermin, a myelinating oligodendrocytespecific protein that regulates cell morphology. J Neurosci 26:757–762.
   Google Scholar
• Brun P, Bégou M, Andrieux A, Mouly-Badina L, Clerget M, Schweitzer A, . 2005. Dopaminergic transmission in STOP null mice. J Neurochem 94:63–73.
   PubMedGoogle Scholar
• Bruneel A, Labas V, Mailloux A, Sharma S, Royer N, Vinh J, . 2005. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 5:3876–3884.
   PubMed Web of Science ®Google Scholar
• Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V. 2008. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophr Res 98:118–128.
   PubMed Web of Science ®Google Scholar
• Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, . 2004. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515–17523.
   PubMed Web of Science ®Google Scholar
• Clark D, Dedova I, Cordwell S, Matsumoto I. 2006. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11:459–470.
   PubMed Web of Science ®Google Scholar
• Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. 2003. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160:1100–1109.
   Google Scholar
• Dale LB, Babwah AV, Ferguson SS. 2002. Mechanisms of meta-botropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem Int 41:319–326.
   Google Scholar
• Denarier E, Aguezzoul M, Jolly C, Vourcx'h C, Roure A, Andrieux A, . 1998. Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6). Biochem Biophys Res Commun 243:791–796.
   Google Scholar
• Deng W, Poretz RD. 2003. Oligodendroglia in developmental neurotoxicity. Neurotoxicology 24:161–178.
   PubMed Web of Science ®Google Scholar
• Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. 2006. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531–540.
   PubMedGoogle Scholar
• Du Y, Dreyfus CF. 2006. Oligodendrocytes as providers of growth factors. J Neurosci Res 68:647–654.
   Google Scholar
• Edwards MM, Robinson SR. 2006. TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease. J Neural Transm 113:1709–1715.
   PubMed Web of Science ®Google Scholar
• Ehlers MD, Tingley WG, Huganir RL. 1995. Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. Science 269:1734–1737.
   PubMedGoogle Scholar
• English JA, Dicker P, Föcking M, Dunn MJ, Cotter DR. 2009. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9:3368–3382.
   PubMed Web of Science ®Google Scholar
• Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA. 2000. In vivo investigation of white matter pathology in schizophrenia with magnetization transfer imaging. J Neurol Neurosurg Psychiatry 68:70–74.
   PubMed Web of Science ®Google Scholar
• Greene ND, Bamidele A, Choy M, de Castro SC, Wait R, Leung KY, . 2007. Proteome changes associated with hippocampal MRI abnormalities in the lithium pilocarpine-induced model of convulsive status epilepticus. Proteomics 7:1336–1344.
   Google Scholar
• Gygi SP, Corthals GL, Zhang, Y, Rochon Y, Aebersold, R. 2000. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97:9390–9395.
   PubMed Web of Science ®Google Scholar
• Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, . 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746–4751.
   PubMed Web of Science ®Google Scholar
• Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. 1996. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 180:157–163.
   PubMedGoogle Scholar
• Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, . 1999. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 156:1190–1199.
   PubMed Web of Science ®Google Scholar
• Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. 1999. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 91:1247–1255.
   PubMed Web of Science ®Google Scholar
• Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, . 2008. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13:1118–1128.
   PubMed Web of Science ®Google Scholar
• Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. 2000. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142–149.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30.
   PubMed Web of Science ®Google Scholar
• Katsel P, Davis KL, Haroutunian V. 2005. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 79:157–173.
   PubMed Web of Science ®Google Scholar
• Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ, . 2008. Metabolic changes in schizophrenia and human brain evolution. Genome Biol 9:R124.
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Yamada K, Kohmura E, Hayakawa T. 1990. Effect of astrocyte-derived factors on ischemic brain edema induced by rat MCA occlusion. APMIS 98(9):851–857.
   Google Scholar
• Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, . 2005. DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity. Neuroimage 15:1109–1118.
   Google Scholar
• Larsen TK, Opjordsmoen S. 1996. Early identification and treatment of schizophrenia: conceptual and ethical considerations. Psychiatry 59:371–380.
   Web of Science ®Google Scholar
• Lewis DA, Levitt P. 2002. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409–432.
   PubMed Web of Science ®Google Scholar
• Liang P, MacRae TH. 1997. Molecular chaperones and the cytoskeleton. J Cell Sci 110:1431–40.
   PubMed Web of Science ®Google Scholar
• Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, . 1999. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17:676–680.
   PubMed Web of Science ®Google Scholar
• Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER. 2003. Tumor suppression by the prohibitin gene 3′ untranslated region RNA in human breast cancer. Cancer Res 63:5251–5256.
   PubMed Web of Science ®Google Scholar
• Marenco S, Weinberger DR. 2000. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527.
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, . 2009a. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275–289.
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyás E, Eberlin MN, . 2009b. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43:978–986.
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW. 2009c. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:151–163.
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, Dias-Neto E. 2009d. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 9:17.
   PubMed Web of Science ®Google Scholar
• McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH. 2007. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 90:15–27.
   PubMed Web of Science ®Google Scholar
• Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. 2002. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22:2718–2729.
   PubMed Web of Science ®Google Scholar
• Middleton FA, Peng L, Lewis DA, Levitt P, Mimics K. 2005. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology 30:974–983.
   PubMed Web of Science ®Google Scholar
• Mishra S, Murphy LC, Murphy LJ. 2006. The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 10:353–363.
   PubMed Web of Science ®Google Scholar
• Moore C, Perry AC, Love S, Hall L. 1996. Sequence analysis and immunolocalisation of phosphatidylethanolamine binding protein (PBP) in human brain tissue. Brain Res Mol Brain Res 37:74–78.
   Google Scholar
• Müller N, Schwarz MJ. 2008. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258:97–106.
   PubMedGoogle Scholar
• Nicholl ID, Quinlan RA. 1994. Chaperone activity of alpha-crystallins modulates intermediate filament assembly. EMBO J 13:945–953.
   PubMedGoogle Scholar
• Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, . 2009. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13:1102–17.
   Google Scholar
• Pennington K, Dicker P, Dunn MJ, Cotter DR. 2008. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8:5097–5107.
   PubMed Web of Science ®Google Scholar
• Perkins DO. 2007. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention. CNS Spectr 12:10–13.
   Google Scholar
• Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, . 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684–697, 643.
   PubMed Web of Science ®Google Scholar
• Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2007. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6:141–149.
   PubMed Web of Science ®Google Scholar
• Puricelli L, Iori E, Millioni R, Arrigoni G, James P, Vedovato M, Tessari P. 2006. Proteome analysis of cultured fibroblasts from type 1 diabetic patients and normal subjects. J Clin Endocrinol Metab 91:3507–3514.
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Addington AM, Frangou S, Psych MR. 2005. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434–49.
   PubMed Web of Science ®Google Scholar
• Schoentgen F, Jollès P. 1995. From structure to function: possible biological roles of a new widespread protein family binding hydrophobic ligands and displaying a nucleotide binding site. FEBS Lett 369:22–26.
   PubMedGoogle Scholar
• Segal D, Koschnick JR, Slegers LH, Hof PR. 2007. Oligodendrocyte pathophysiology: a new view of schizophrenia. Int J Neuropsychopharmacol 10:503–511.
   PubMed Web of Science ®Google Scholar
• Seliger B, Dressler SP, Wang E, Kellner R, Recktenwald CV, Lottspeich F, . 2009. Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 9:1567–1581.
   Google Scholar
• Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, . 2008. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420–31.
   PubMed Web of Science ®Google Scholar
• Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. 2007. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl 1:1291–1305.
   PubMed Web of Science ®Google Scholar
• Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A, . 2008. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry 13:878–896.
   PubMedGoogle Scholar
• Smutzer G, Lee VM, Trojanowski JQ, Arnold SE. 1998. Human olfactory mucosa in schizophrenia. Ann Otol Rhinol Laryngol 107:349–355.
   Google Scholar
• Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. 2008. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 103:71–82.
   PubMed Web of Science ®Google Scholar
• Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, . 2006. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 31:1–13.
   Google Scholar
• Strous RD, Shoenfeld Y. 2006. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 27(2):71–80.
   Google Scholar
• Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA. 2007. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11:153–164.
   PubMedGoogle Scholar
• Sweitzer SM, Hinshaw JE. 1998. Dynamin undergoes a GTP-dependent conformational change causing vesiculation. Cell 93(6):1021–1029.
   Google Scholar
• Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT. 1992. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522–530.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Dijkstra C, Polman C. 2005. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4:32–41.
   PubMed Web of Science ®Google Scholar
• Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, . 2003. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798–805.
   PubMed Web of Science ®Google Scholar
• van Os J, Rutten BPF, Poulton R. 2010. Gene-environment interactions for searchers: Collaboration between epidemiology and molecular genetics. Gattaz WF, Busatto G. Advances in Schizophrenia Research. New York: Springer. 19–50.
   Google Scholar
• Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM, . 2001. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55:641–650.
   PubMed Web of Science ®Google Scholar
• Virgo L, Humphries C, Mortimer A, Barnes T, Hirsch S, de Belleroche J. 1995. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry 37:694–701.
   PubMedGoogle Scholar
• Voineskos AN, de Luca V, Bulgin NL, van Adrichem Q, Shaikh S, Lang DJ, . 2008. A family-based association study of the myelin-associated glycoprotein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase genes with schizophrenia. Psychiatr Genet 18:143–146.
   PubMedGoogle Scholar
• Wang S, Fusaro G, Padmanabhan J, Chellappan SP. 2002. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 21:8388–8396.
   PubMed Web of Science ®Google Scholar
• Webster MJ, O'Grady J, Kleinman JE, Weickert CS. 2005. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133:453–461.
   PubMed Web of Science ®Google Scholar
• Willson VJ, Graham JG, McQueen IN, Thompson RJ. 1980. Immunoreactive aldolase C in cerebrospinal fluid of patients with neurological disorders. Ann Clin Biochem 17:110–113.
   Google Scholar
• Wong AH, Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, . 2005. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr Res 78:137–146.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Hige T, Takahashi T. 2005. Vesicle endocytosis requires dynamin-dependent GTP hydrolysis at a fast CNS synapse. Science 307:124–127.
   Google Scholar
• Yao JK, Reddy RD, van Kammen DP. 2001. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287–310.
   PubMed Web of Science ®Google Scholar
• Yung AR, Killackey EJ, Nelson B, McGorry PD. 2010. The impact of early intervention in schizophrenia. Gattaz WF, Busatto G. Advances in Schizophrenia Research. New York: Springer. in press.
   Google Scholar
• Zheng X, Wu SL, Hincapie M, Hancock WS. 2009. Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 1216:3538–3545.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Baker K, Terracciano LM, Lugli A. 2008. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 14:3798–3806.
   PubMed Web of Science ®Google Scholar